Literature DB >> 11169529

Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha.

S C Hartsel1, B Baas, E Bauer, L T Foree, K Kindt, H Preis, A Scott, E H Kwong, M Ramaswamy, K M Wasan.   

Abstract

The purpose of the present study was to examine the influence of heat-induced superaggregation of Amphotericin B (AmB) in the Fungizone (FZ) formulation on its interaction with human serum components and relate this to reduced toxicity. Whole serum distribution studies showed that a significantly lower percentage of AmB from HFZ was recovered in the high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride-rich lipoprotein (TRL) fractions and a greater percentage recovered in the lipoprotein-deficient plasma (LPDP), though the majority of both preparations were recovered in LPDP. Circular dichroism (CD) and difference absorption spectroscopy were used to determine the stability of FZ and heat-treated FZ (HFZ) in the presence of HDL, LDL, serum, and albumin. The CD studies indicate that the "core" aggregate of HFZ is more stable in the presence of HDL and LDL, whereas the FZ is less stable and more dynamic with the core aggregate dissociating to a greater extent in the presence of either purified lipoprotein. Absorption studies with whole serum and purified albumin suggest that FZ aggregates are far less stable in the presence of albumin than HFZ and that interaction with serum albumin is a dominant feature for both drug preparations. HFZ also has a different effect on the cytokine response in vitro. Studies using THP-1 human monocytes show that HFZ provokes a smaller release of tumor necrosis factor (TNF)-alpha than FZ. This cytokine may be associated with the unpleasant side effects of AmB. These findings suggest that heat-induced superaggregation of AmB alters its interaction with HDL, LDL, serum proteins, and monocytes, and these findings may be important in explaining the reduced toxicity of the superaggregated form of AmB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169529     DOI: 10.1002/1520-6017(200102)90:2<124::aid-jps3>3.0.co;2-x

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

Authors:  E H Kwong; M Ramaswamy; E A Bauer; S C Hartsel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

4.  Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation.

Authors:  S Rama Iñiguez; M A Dea-Ayuela; J A Sanchez-Brunete; J J Torrado; J M Alunda; F Bolas-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.

Authors:  Ying Hong; Peter J Shaw; Bruce N Tattam; Christa E Nath; John W Earl; Katherine R Stephen; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2006-12-19       Impact factor: 2.953

6.  Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.

Authors:  Olena Sivak; Karen Bartlett; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

8.  Effect of heat-treated amphotericin B on renal and fungal cytotoxicity.

Authors:  Karen Bartlett; Edwin Yau; Scott C Hartsel; Alison Hamer; Gina Tsai; Dan Bizzotto; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 9.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

10.  How can micelle systems be rebuilt by a heating process?

Authors:  Miguel Adelino da Silva-Filho; Scheyla Daniela Vieira da Silva Siqueira; Larissa Bandeira Freire; Ivonete Batista de Araújo; Káttya Gyselle de Holanda e Silva; Aldo da Cunha Medeiros; Irami Araújo-Filho; Anselmo Gomes de Oliveira; Eryvaldo Sócrates Tabosa do Egito
Journal:  Int J Nanomedicine       Date:  2012-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.